Last update 22 Jun 2024
Lumretuzumab
Last update 22 Jun 2024
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms anti-HER3 monoclonal antibody, GE-HuMAb-HER3, HER3 MAb solid tumours + [3] |
Target |
Mechanism HER3 antagonists(Receptor tyrosine-protein kinase erbB-3 antagonists) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Gene Sequence
Sequence Code 185052L
Source: *****
Sequence Code 315616297H
Source: *****
Related
3
Clinical Trials associated with LumretuzumabOpen Label Phase Ib/II, Multicenter Study of the Combination of RO5479599 With Carboplatin and Paclitaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) of Squamous Histology Who Have Not Received Prior Chemotherapy or Targeted Therapy for NSCLC
A multi-center Phase Ib/II study of the combination of RO5479599 with carboplatin and paclitaxel once in every 3 week (q3w) regimen to evaluate the safety and tolerability.
Start Date01 Oct 2014 |
Sponsor / Collaborator |
Phase IB, Open-Label, Multicenter, Dose-Escalation Study Followed by an Extension Phase to Evaluate the Safety, Pharmacokinetics and Activity of RO5479599, a Glycoengineered Antibody Against HER3, Administered in Combination With Pertuzumab and Paclitaxel in Patients With Metastatic Breast Cancer Expressing HER3 & HER2 Protein
This multicenter, open-label dose-escalation study with an extension phase will evaluate the safety and pharmacokinetics of lumretuzumab in combination with pertuzumab and paclitaxel in participants with metastatic breast cancer expressing HER3 and HER2 protein. Cohorts of participants will receive escalating doses of lumretuzumab intravenously (IV) every three weeks (Q3W) in combination with pertuzumab 840 milligrams (mg) IV initial dose followed by 420 mg IV Q3W and paclitaxel 80 milligrams per square meter (mg/m^2) IV weekly. After completion of dose-limiting toxicity period (21 days), the study will be conducted in two extension phase cohorts: Cohort 1 and Cohort 2. Enrollment in Extension Phase Cohort 2 will occur only upon completion of Extension Phase Cohort 1. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.
Start Date06 Aug 2013 |
Sponsor / Collaborator |
Phase Ia/Ib, Open-Label, Multicenter, Dose-Escalation Study Followed by an Extension Phase to Evaluate the Safety, Pharmacokinetics and Activity of RO5479599, A Glycoengineered Antibody Against HER3, Administered Either Alone (Part A) or in Combination With Cetuximab (Part B) or in Combination With Erlotinib (Part C) in Patients With Metastatic and/or Locally Advanced Malignant HER3-Positive Solid Tumors of Epithelial Cell Origin
This dose-escalating study consists of 3 parts (A, B and C) and will evaluate the safety, pharmacokinetics and efficacy of RO5479599, alone or in combination with cetuximab or erlotinib, in participants with metastatic and/or locally advanced malignant HER3-positive solid tumors. Cohorts of participants will receive escalating doses of intravenous RO5479599 as monotherapy (Part A) or in combination with cetuximab (in Part B) or with erlotinib (in Part C) followed by an extension phase for each part.
In an imaging substudy, participants will receive one or two doses of zirconium-89-labeled RO5479599 (89ZrRO5479599) in addition to unlabeled RO5479599 to evaluate the in vivo biodistribution and organ pharmacokinetics of RO5479599.
In an imaging substudy, participants will receive one or two doses of zirconium-89-labeled RO5479599 (89ZrRO5479599) in addition to unlabeled RO5479599 to evaluate the in vivo biodistribution and organ pharmacokinetics of RO5479599.
Start Date01 Dec 2011 |
Sponsor / Collaborator |
100 Clinical Results associated with Lumretuzumab
Login to view more data
100 Translational Medicine associated with Lumretuzumab
Login to view more data
100 Patents (Medical) associated with Lumretuzumab
Login to view more data
41
Literatures (Medical) associated with Lumretuzumab15 Jan 2024·Current medicinal chemistry
The Therapeutic Significance of HER3 in Non-small Cell Lung Cancer
(NSCLC): A Review Study
Article
Author: Ding, Ke ; Zhang, Jinwei ; Trinder, Amelia
Abstract::
HER3 (Human Epidermal Growth Factor Receptor 3) is frequently overexpressed
in various cancers, including non-small cell lung cancer (NSCLC), with a prevalence
of 83% in primary tumors. Its involvement in tumorigenesis and resistance to targeted
therapies makes HER3 a promising target for cancer treatment. Despite being initially
considered “undruggable” due to its lack of catalytic activity, significant progress
has been made in the development of anti-HER3 therapeutics. Monoclonal antibodies
such as lumretuzumab, seribantumab, and patritumab have shown potential in targeting
HER3 to overcome resistance to epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs). Additionally, antibody-drug conjugates (ADCs) like HER3-DXd
(patritumab deruxtecan) are new drug candidates that have demonstrated selective delivery
of cytotoxic chemicals to NSCLC cells by exploiting HER3's widespread expression,
minimizing cytotoxicity. This review aims to evaluate the efficacy of current
HER3 therapeutics in development and their therapeutic potential in NSCLC, incorporating
evidence from clinical trials.
01 Aug 2023·Annals of oncology : official journal of the European Society for Medical Oncology
Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study
Article
Author: Cejalvo, J M ; Pernas, S ; Tolosa, P ; Oliveira, M ; Espinosa-Bravo, M ; Sellami, D ; Prat, A ; Fan, P-D ; Esker, S ; Luna, A M ; Ferrero-Cafiero, J M ; González-Farré, B ; Parul, P ; Arumi, M ; Santhanagopal, A ; Izarzugaza, Y ; Salvador-Bofill, F J ; Pascual, T ; Vidal, M ; Martínez-Sáez, O ; Falato, C ; Cruz, J ; Vila, M Margelí ; Ciruelos, E ; Villacampa, G ; Paré, L ; Guerra, J A ; Sanfeliu, E
BACKGROUND:
Patritumab deruxtecan (HER3-DXd) is a human epidermal growth factor receptor 3 (HER3)-directed antibody-drug conjugate composed of a fully human anti-HER3 monoclonal antibody (patritumab) covalently linked to a topoisomerase I inhibitor payload via a stable, tumor-selective, tetrapeptide-based cleavable linker. TOT-HER3 is a window-of-opportunity study designed to assess the biological activity, measured by CelTIL score [= -0.8 × tumor cellularity (in %) + 1.3 × tumor-infiltrating lymphocytes (TILs) (in %)], and clinical activity of HER3-DXd during short-term (21 days) pre-operative treatment in patients with primary operable HER2-negative early breast cancer.
PATIENTS AND METHODS:
Patients with previously untreated hormone receptor-positive/HER2-negative tumors were allocated to one of four cohorts according to baseline ERBB3 messenger RNA expression. All patients received one dose of HER3-DXd 6.4 mg/kg. The primary objective was to evaluate change from baseline in CelTIL score.
RESULTS:
Seventy-seven patients were evaluated for efficacy. A significant change in CelTIL score was observed, with a median increase from baseline of 3.5 (interquartile range, -3.8 to 12.7; P = 0.003). Among patients assessable for clinical response (n = 62), an overall response rate of 45% was observed (tumor measurement by caliper), with a trend toward an increase in CelTIL score among responders compared with non-responders (mean difference, +11.9 versus +1.9). Change in CelTIL score was independent of baseline ERBB3 messenger RNA and HER3 protein levels. Genomic changes occurred, including switching toward a less proliferative tumor phenotype based on PAM50 subtypes, suppression of cell proliferation genes, and induction of genes associated with immunity. Treatment-emergent adverse events were observed in 96% of patients (14% grade ≥3); most common were nausea, fatigue, alopecia, diarrhea, vomiting, abdominal pain, and neutrophil count decrease.
CONCLUSIONS:
A single dose of HER3-DXd was associated with clinical response, increased immune infiltration, suppression of proliferation in hormone receptor-positive/HER2-negative early breast cancer, and a tolerable safety profile consistent with previously reported results. These findings support further study of HER3-DXd in early breast cancer.
01 Feb 2023·ESMO open
Targeting HER3 for cancer treatment: a new horizon for an old target
Review
Author: Uliano, J ; Curigliano, G ; Corvaja, C ; Tarantino, P
Human epidermal growth factor receptor 3 (HER3) is a member of the human epidermal growth factor receptors family, having as its main ligands neuregulins 1 and 2. Although its poor tyrosine kinase activity entails a weak oncogenic power on its own, HER3 can heterodimerize with HER2 and/or epidermal growth factor receptor (EGFR), leading to a drastic enhancement of transphosphorylation and activation of downstream signaling pathways, ultimately promoting oncogenesis, metastatic dissemination, and drug resistance. Given its ubiquitous expression across solid tumors, multiple efforts have been done to therapeutically target HER3 by blocking either the ligand binding domain or its dimerization with other receptors. Treatment with anti-HER3 monoclonal antibodies or bispecific antibodies, both as single agents and in combination with other compounds, unfortunately led to unsatisfactory results across several tumor types. The HER3-directed delivery of cytotoxic payloads through antibody-drug conjugates has recently demonstrated encouraging activity in several tumor types, however, suggesting a potential role for the therapeutic targeting of HER3 in cancer treatment.
20
News (Medical) associated with Lumretuzumab08 Apr 2024
-- On-track to nominate development candidate in 2024 --
BOSTON, April 8, 2024 /PRNewswire/ -- Elevation Oncology Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced new preclinical data demonstrating proof-of-concept for its differentiated HER3-ADC program. The data will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, California.
"We are pleased to share the first preclinical proof-of-concept data for our HER3-ADC program, reinforcing our commitment to advancing a portfolio of differentiated ADC-based therapies that may deliver better outcomes for patients," said David Dornan, Ph.D., Chief Scientific Officer of Elevation Oncology. "With our HER3-ADC program, we set out to design a differentiated ADC which selectively binds to HER3 and is internalized to potentially attack HER3-expressing cancerous cells while minimizing systemic exposure. Preclinical data with our proof-of-concept HER3-ADC shows HER3-dependent cell killing and robust anti-tumor activity in vivo where HER3 is expressed at high levels. We look forward to nominating a development candidate from our HER3 program later this year and, subsequently, advancing our program closer to the clinic."
HER3 is a clinically validated oncology and antibody-drug conjugate (ADC) target, which is overexpressed in a range of solid tumors, including breast cancer, EGFR-mutant non-small cell lung cancer and pancreatic cancer, and is often associated with poor clinical outcomes. Elevation Oncology's HER3-ADC program conjugated seribantumab, its anti-HER3 monoclonal antibody, with a cleavable valine-citrulline linker and monomethyl auristatin E (MMAE) payload to yield HER3-ADC1, a proof-of-concept molecule with an average drug-antibody ratio (DAR) of 4.
In a poster titled, "Therapeutic potential of a HER3 antibody-drug conjugate for the treatment of HER3-expressing cancers," Elevation Oncology scientists presented in vitro and in vivo data of a seribantumab-based ADC for patients with HER3-expressing cancers. The data showed:
HER3-ADC1 binding to cancer cells, endocytosis, MMAE release and inhibition of proliferation were dependent on HER3 expression.
In cytotoxicity assays, HER3-ADC1 displayed HER3-dependent cell killing and outperformed a benchmark HER3-ADC with a deruxtecan payload, which is currently in clinical development.
In a patient derived xenograft (PDX) model of pancreatic cancer with high HER3 expression, HER3-ADC1 induced tumor regression, whereas an isotype-MMAE control and a benchmark HER3-ADC with a deruxtecan payload had only a modest effect.
The poster presentation is now available in the "Publications" section of Elevation Oncology's website: .
About Elevation Oncology, Inc.
Elevation Oncology is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. We are leveraging our antibody-drug conjugate (ADC) expertise to advance a novel pipeline, initially targeting two clinically validated targets in oncology, Claudin 18.2 and HER3. Our lead candidate, EO-3021, is a potential best-in-class ADC designed to target Claudin 18.2 and is currently being evaluated in a Phase 1 trial (NCT05980416) in patients with advanced, unresectable or metastatic solid tumors likely to express Claudin 18.2 including gastric, gastroesophageal junction, pancreatic or esophageal cancers. Additionally, we expect to nominate a development candidate for our second program, a HER3-targeting ADC for the treatment of patients with solid tumors that overexpress HER3, in 2024. For more information, visit .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated clinical and preclinical development activities, expected timing of announcements regarding development activities, potential benefits of Elevation Oncology's product candidates, potential market opportunities for Elevation Oncology's product candidates and the ability of Elevation Oncology's product candidates to treat their targeted indications. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These forward-looking statements may be accompanied by such words as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "might," "plan," "possible," "potential," "will," "would," and other words and terms of similar meaning. Although Elevation Oncology believes that the expectations reflected in such forward-looking statements are reasonable, Elevation Oncology cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval are inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause Elevation Oncology's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to Elevation Oncology's ability to advance its product candidates, the timing and results of preclinical studies and clinical trials, approvals and commercialization of product candidates, the receipt and timing of potential regulatory designations, Elevation Oncology's ability to fund development activities and achieve development goals, Elevation Oncology's ability to protect intellectual property, Elevation Oncology's ability to establish and maintain collaborations with third parties, and other risks and uncertainties described under the heading "Risk Factors" in documents Elevation Oncology files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and Elevation Oncology undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
Elevation Oncology Investor and Media Contact
Candice Masse, 978-879-7273
Senior Director, Corporate Communications & Investor Relations
cmasse@elevationoncology.com
Company Codes: NASDAQ-NMS:ELEV
Phase 1ADCAACR
13 Mar 2024
SINGAPORE and HANOVER, Germany, March 13, 2024 /PRNewswire/ -- Hummingbird Bioscience and Dartmouth's Geisel School of Medicine today announced that the 3rd Annual VISTA Symposium will take place virtually on Wednesday, March 27, 2024 (11:00 AM - 3:30 PM ET).
VISTA is a novel immune checkpoint implicated in various cancers. There is broad potential clinical impact for cancer patients, with strong scientific evidence that VISTA-mediated immune suppression plays a key role in many solid tumors, including triple-negative breast cancer, non-small cell lung cancer and head and neck squamous cell carcinoma. High VISTA expression in tumor correlates with poor survival in cancer patients and has been associated with a lack of response to other immune checkpoint inhibitors. Pre-clinical data on VISTA biology and VISTA targeting have shown potent anti-tumor effects, and clinical readouts are expected this year.
The symposium will explore the important role of VISTA in cancer immunotherapy. Along with updates on the ongoing clinical development of anti-VISTA therapies, renowned scientific experts, clinicians, and industry leaders will share the latest insights on VISTA biology, and the growing potential of VISTA as a therapeutic target in multiple cancer indications. Register here.
Symposium Information
Title: 3rd Annual VISTA Symposium: VISTA – Clinical updates and biological insights on a promising new target in cancer immunotherapy
Date: Wednesday, March 27, 2024
Time: 11:00 AM - 3:30 PM ET
Following a keynote presentation by
John Connolly, PhD (Chief Scientific Officer, Parker Institute for Cancer Immunotherapy), the day will include short presentations, panel discussions and Q&A sessions by VISTA experts that will contextualize the exciting data and highlight why VISTA is the immunotherapy target to watch in 2024.
Agenda
Opening Remarks (11:00 AM - 11:10 AM ET)
Piers Ingram, PhD – Chief Executive Officer and Co-Founder, Hummingbird Bioscience
Keynote (11:10 AM - 11:30 AM ET)
John Connolly, PhD – Chief Scientific Officer, Parker Institute for Cancer Immunotherapy
VISTA Biology (11:30 AM - 12:30 PM ET)
Randolph Noelle, PhD – Emeritus Professor of Microbiology and Immunology, Geisel School of Medicine
J. Louise Lines, PhD – Research Scientist, Geisel School of Medicine
Li Lily Wang, PhD – Associate Staff, Lerner Research Institute, Cleveland Clinic
Sietse J. Luk, MD – Research Scientist, Department of Hematology, Leiden University Medical Center
VISTA Targeting and Potential Biomarkers (12:30 PM - 1:15 PM ET)
Bhushan Dharmadhikari, PhD – Principal Scientist, Hummingbird Bioscience
Sven Mostböck, PhD – Principal Scientist, Boehringer Ingelheim
Robert Martell, MD, PhD – Chief Scientific Officer, Curis
VISTA and Clinical Opportunities (1:30 PM - 2:30 PM ET)
Joshua Gruber, MD, PhD – Assistant Professor, Department of Internal Medicine, University of Texas, Southwestern Medical Center
P. Jack Hoopes, DVM, PhD – Professor of Surgery, Professor of Medicine, Geisel School of Medicine
Jing Fu, PhD – Research Scientist, Vagelos College of Physicians and Surgeons, Columbia University
Matthew Vesely, MD, PhD – Assistant Professor of Dermatology, Yale School of Medicine
Anti-VISTA Immunotherapies in Clinical Development (2:30 PM – 3:30 PM ET)
Edward van der Horst, PhD – Chief Scientific Officer, Sensei Bio
Jerome Boyd-Kirkup, PhD – Chief Scientific Officer and Co-Founder, Hummingbird Bioscience
Thierry Guillaudeux, PhD – Chief Scientific Officer, Kineta
Follow this link for updates.
About Hummingbird Bioscience
Hummingbird Bioscience is a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases. The Hummingbird Bioscience model combines computational and systems biology with wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development. The company harnesses this integrated approach across target identification and patient selection, enabling the team to increase the efficiency of translating novel scientific insights while reducing the inherent risk in drug discovery and development. The company is currently developing two clinical-stage assets: HMBD-001, a humanized anti-HER3 monoclonal antibody targeting a novel epitope on HER3, and HMBD-002, a humanized anti-VISTA IgG4 monoclonal antibody. Both programs are currently in Phase I studies. At Hummingbird Bioscience, the commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic.
For more information, please visit , and follow Hummingbird Bioscience on LinkedIn, X (formerly Twitter), and YouTube.
About Geisel School of Medicine
Founded in 1797, the Geisel School of Medicine at Dartmouth strives to improve the lives of the communities it serves through excellence in learning, discovery, and healing. The Geisel School of Medicine is renowned for its leadership in medical education, healthcare policy and delivery science, biomedical research, global health, and in creating innovations that improve lives worldwide. As one of America's leading medical schools, Dartmouth's Geisel School of Medicine is committed to training new generations of diverse leaders who will help solve our most vexing challenges in healthcare.
Hummingbird Bioscience Contacts:
Crystal Ho
[email protected]
[email protected]
+65 6979 5580
[email protected]
Geisel School of Medicine Contacts:
Derik Hertel
Director of Communications & Marketing
Phone: (603) 646-5100
Email: [email protected]
[email protected]
Phase 1Immunotherapy
13 Mar 2024
SINGAPORE and HANOVER, Germany, March 13, 2024 /PRNewswire/ -- Hummingbird Bioscience and Dartmouth's Geisel School of Medicine today announced that the 3rd Annual VISTA Symposium will take place virtually on Wednesday, March 27, 2024 (11:00 AM - 3:30 PM ET).
VISTA is a novel immune checkpoint implicated in various cancers. There is broad potential clinical impact for cancer patients, with strong scientific evidence that VISTA-mediated immune suppression plays a key role in many solid tumors, including triple-negative breast cancer, non-small cell lung cancer and head and neck squamous cell carcinoma. High VISTA expression in tumor correlates with poor survival in cancer patients and has been associated with a lack of response to other immune checkpoint inhibitors. Pre-clinical data on VISTA biology and VISTA targeting have shown potent anti-tumor effects, and clinical readouts are expected this year.
The symposium will explore the important role of VISTA in cancer immunotherapy. Along with updates on the ongoing clinical development of anti-VISTA therapies, renowned scientific experts, clinicians, and industry leaders will share the latest insights on VISTA biology, and the growing potential of VISTA as a therapeutic target in multiple cancer indications. Register here.
Symposium Information
Title: 3rd Annual VISTA Symposium: VISTA – Clinical updates and biological insights on a promising new target in cancer immunotherapy
Date: Wednesday, March 27, 2024
Time: 11:00 AM - 3:30 PM ET
Following a keynote presentation by
John Connolly, PhD (Chief Scientific Officer, Parker Institute for Cancer Immunotherapy), the day will include short presentations, panel discussions and Q&A sessions by VISTA experts that will contextualize the exciting data and highlight why VISTA is the immunotherapy target to watch in 2024.
Agenda
Opening Remarks (11:00 AM - 11:10 AM ET)
Piers Ingram, PhD – Chief Executive Officer and Co-Founder, Hummingbird Bioscience
Keynote (11:10 AM - 11:30 AM ET)
John Connolly, PhD – Chief Scientific Officer, Parker Institute for Cancer Immunotherapy
VISTA Biology (11:30 AM - 12:30 PM ET)
Randolph Noelle, PhD – Emeritus Professor of Microbiology and Immunology, Geisel School of Medicine
J. Louise Lines, PhD – Research Scientist, Geisel School of Medicine
Li Lily Wang, PhD – Associate Staff, Lerner Research Institute, Cleveland Clinic
Sietse J. Luk, MD – Research Scientist, Department of Hematology, Leiden University Medical Center
VISTA Targeting and Potential Biomarkers (12:30 PM - 1:15 PM ET)
Bhushan Dharmadhikari, PhD – Principal Scientist, Hummingbird Bioscience
Sven Mostböck, PhD – Principal Scientist, Boehringer Ingelheim
Robert Martell, MD, PhD – Chief Scientific Officer, Curis
VISTA and Clinical Opportunities (1:30 PM - 2:30 PM ET)
Joshua Gruber, MD, PhD – Assistant Professor, Department of Internal Medicine, University of Texas, Southwestern Medical Center
P. Jack Hoopes, DVM, PhD – Professor of Surgery, Professor of Medicine, Geisel School of Medicine
Jing Fu, PhD – Research Scientist, Vagelos College of Physicians and Surgeons, Columbia University
Matthew Vesely, MD, PhD – Assistant Professor of Dermatology, Yale School of Medicine
Anti-VISTA Immunotherapies in Clinical Development (2:30 PM – 3:30 PM ET)
Edward van der Horst, PhD – Chief Scientific Officer, Sensei Bio
Jerome Boyd-Kirkup, PhD – Chief Scientific Officer and Co-Founder, Hummingbird Bioscience
Thierry Guillaudeux, PhD – Chief Scientific Officer, Kineta
Follow this link for updates.
About Hummingbird Bioscience
Hummingbird Bioscience is a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases. The Hummingbird Bioscience model combines computational and systems biology with wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development. The company harnesses this integrated approach across target identification and patient selection, enabling the team to increase the efficiency of translating novel scientific insights while reducing the inherent risk in drug discovery and development. The company is currently developing two clinical-stage assets: HMBD-001, a humanized anti-HER3 monoclonal antibody targeting a novel epitope on HER3, and HMBD-002, a humanized anti-VISTA IgG4 monoclonal antibody. Both programs are currently in Phase I studies. At Hummingbird Bioscience, the commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic.
For more information, please visit , and follow Hummingbird Bioscience on LinkedIn, X (formerly Twitter), and YouTube.
About Geisel School of Medicine
Founded in 1797, the Geisel School of Medicine at Dartmouth strives to improve the lives of the communities it serves through excellence in learning, discovery, and healing. The Geisel School of Medicine is renowned for its leadership in medical education, healthcare policy and delivery science, biomedical research, global health, and in creating innovations that improve lives worldwide. As one of America's leading medical schools, Dartmouth's Geisel School of Medicine is committed to training new generations of diverse leaders who will help solve our most vexing challenges in healthcare.
Hummingbird Bioscience Contacts:
Crystal Ho
[email protected]
[email protected]
+65 6979 5580
[email protected]
Geisel School of Medicine Contacts:
Derik Hertel
Director of Communications & Marketing
Phone: (603) 646-5100
Email: [email protected]
[email protected]
SOURCE Hummingbird Bioscience
Phase 1Immunotherapy
100 Deals associated with Lumretuzumab
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D11239 | Lumretuzumab | - |
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Non-Small Cell Lung Cancer | Phase 2 | CA | 01 Oct 2014 | |
| Non-Small Cell Lung Cancer | Phase 2 | DK | 01 Oct 2014 | |
| Non-Small Cell Lung Cancer | Phase 2 | ES | 01 Oct 2014 | |
| Squamous non-small cell lung cancer | Phase 2 | CA | 01 Oct 2014 | |
| Squamous non-small cell lung cancer | Phase 2 | DK | 01 Oct 2014 | |
| Squamous non-small cell lung cancer | Phase 2 | ES | 01 Oct 2014 | |
| Breast Cancer | Phase 2 | - | - | |
| Metastatic breast cancer | Phase 1 | DK | 06 Aug 2013 | |
| Metastatic breast cancer | Phase 1 | FR | 06 Aug 2013 | |
| Metastatic breast cancer | Phase 1 | DE | 06 Aug 2013 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
| Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
|---|
Phase 1/2 | Squamous non-small cell lung cancer First line | 12 | ientqxowdi(qyutoybyff) = gastrointestinal, haematological and nervous system toxicities apkofpioyd (xekgcxlnbl ) | Positive | 22 Jul 2019 | ||
Phase 1 | 120 | djtquxzulz(muiifalqyz) = The most frequent adverse events were gastrointestinal and skin toxicities, which were manageable. pffjniycip (yfkzzipmli ) | Negative | 15 Sep 2017 | |||
Phase 1 | 13 | rklkfbhwac(rkfrrhpbxa) = zutdcbxylm mrmpsiskoj (kynskjqlub, ±1.8) | - | 20 May 2016 | |||
Phase 1 | 13 | nwvekoxyob(rmyapkrpba) = qhvzsyovnj apdkkozune (kirkznysys ) View more | - | 20 May 2014 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free